Goldman Sachs sees shares of Biohaven rallying 114% after plunging 72% over the past 12 months.
Get this delivered to your inbox, and more info about our products and services.
RBC's $22 price target implies an upside of 74% for shares of Biohaven.
The investment bank upgraded the pharma stock to overweight from equal weight.
The bank initiated the clinical-stage biotechnology firm at a buy rating.
Chart analyst Frank Cappelleri breaks down the technical outlook on the biotech stock.
David Keller breaks down the technicals on this biotech giant.
MBX Biosciences has rallied more than 230% over the past year, but there's room for still more upside from current levels,…
